



EMLc

ATC codes: L04AB04

|                          |                                                                                                                                                                                                                                                                                        |
|--------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indication               | Axial spondyloarthritis ICD11 code: FA92.0Z                                                                                                                                                                                                                                            |
| INN                      | Adalimumab                                                                                                                                                                                                                                                                             |
| Medicine type            | Biological agent                                                                                                                                                                                                                                                                       |
| List type                | Complementary (EML)<br>(EMLc)                                                                                                                                                                                                                                                          |
| Additional notes         | EML: certolizumab pegol, etanercept, golimumab and infliximab are alternatives, including quality-assured biosimilars. EMLc: etanercept and infliximab are alternatives, including quality-assured biosimilars.                                                                        |
| Formulations             | Parenteral > General injections > SC: 40 mg per 0.8 mL ; 40 mg per 0.4 mL ; 10 mg per 0.2 mL (EMLc) ; 20 mg per 0.4 mL (EMLc)                                                                                                                                                          |
| EML status history       | First added in 2019 (TRS 1021)<br>Changed in 2023 (TRS 1049)                                                                                                                                                                                                                           |
| Sex                      | All                                                                                                                                                                                                                                                                                    |
| Age                      | Also recommended for children                                                                                                                                                                                                                                                          |
| Therapeutic alternatives | certolizumab pegol (ATC codes: L04AB05)<br>etanercept (ATC codes: L04AB01)<br>golimumab (ATC codes: L04AB06)<br>infliximab (ATC codes: L04AB02)                                                                                                                                        |
| Patent information       | Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit <a href="http://www.MedsPal.org">www.MedsPal.org</a><br>Read more <a href="#">about patents.</a> |

Tags

Biological

Wikipedia

[Adalimumab](#)

DrugBank

[Adalimumab](#)

## Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of new strength formulations of adalimumab (injection 10 mg/0.2 mL and 20 mg/0.4 mL) to the EMLc.

